39 results about "Pneumovirus" patented technology

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The invention relates to a gene chip for detecting pathogen of equine infectious virus. The gene chip comprises a solid phase carrier and an oligonucleotide probe fixed on the carrier, wherein the oligonucleotide probe comprises a detection probe and a quality control probe; and the detection probe is a nucleic acid fragment selected from the nucleotide sequences of rabies virus, equine infectious arteritis virus, equine infectious rhinopneumonitis virus and equine infectious equine infectious anemia virus. The invention also relates to a method for preparing the gene chip and a method for detecting four equine infectious diseases viruses by means of the chip, comprising the steps of probe synthesis, chip preparation and hybridization with a treated and labeled to-be-detected sample. The invention further relates to a reagent kit which is used for detecting pathogen of equine infectious virus and consists of the chip, a sample treatment reagent, a hybridization reagent, a colour-producing reagent and a specification. The gene chip can detect four viruses at the same time, and has the advantages of simple operation, high accuracy and strong repeatability, and the gene chip is of great significance to both laboratory research and production practice.

The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting immune responses to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or decreasing the severity of infection with an infectious agent, including, for exampleand without limitation, lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens may be attached to the core of the nanostructure either non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens may optionally be displayed along asymmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The invention relates to a novel human antibody of a coronavirus rare broad-spectrum epitope and application thereof. A model of successive screening of prototype strain RBD and Beta strain RBD antigens is utilized, conservative target sites are rapidly focused, and the fully human antibody IMCAS-364 which is combined with different epitopes of the RBD and can realize broad-spectrum neutralization of VOC is successfully separated. The affinity of the strain to a prototype strain, Alpha, Beta, Delta and Omicron reaches an nM level. A known epitope antibody competition experiment proves that IMCAS-364 is combined with a rare target position on the inner side surface of RBD and does not compete with a receptor, and the antibody combined with the target position has the characteristic that the antibody does not compete with ACE2 but can neutralize a new crown for the first time. The IMCAS-364 has the potential of being paired with an antibody which plays a neutralizing role through receptor blocking, has the capability affinity of being combined with atypical pneumovirus at nM level, and can be used for developing a neutralizing antibody of a general SARS coronavirus.

Provided are newly identified pneumoviruses that can infect mammals, including dogs cats and potentially humans. Isolated polynucleotides and proteins of the viruses, as well as the isolated viruses themselves are provided. The invention includes compositions and methods for detecting the viruses, methods and compositions for prophylaxis and / or therapy of disease signs that are positively correlated with the presence of the viruses, and isolated cells comprising the viruses. Intact virions, viral proteins, and fragments thereof are also provided.

The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ΔM2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections.

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

This invention relates to the field of medicine and concerns a method for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, which envisages the use of an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for producing the aforesaid compounds, and to pharmaceutical compositions for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, which contain an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention solves the problem of providing a novel agent effective in the treatment of diseases caused by RNA-containing viruses belonging to the enterovirus genus, the metapneumovirus genus, the pneumovirus genus, the respirovirus genus or the alphacoronavirus genus, and DNA-containing viruses belonging to the adenovirus family and the herpesvirus family, and also effective in the prophylaxis and treatment of asthma exacerbations, chronic obstructive pulmonary disease, cystic fibrosis, conjunctivitis, gastroenteritis, hepatitis and myocarditis, and in the prophylaxis and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia or obstructive airways syndrome.

Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and / or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed. The vaccine compositions and methods described herein can be used to prevent metapneumovirus and respiratory syncytial virus infection in humans, respiratory syncytial virus infection in cattle, avian metapneumovirus infection in various avian species, and pneumonia virus of mice in rodents.

Disclosed herein are nanostructures and uses thereof wherein the nanostructures comprise a plurality of first components, each first component comprising a plurality of identical first polypeptides selected from the group consisting of I53dn5A, I53dn5A. 1, and I53dn5A. 2, or variants thereof; and a plurality of second components, each second component comprising a plurality of identical second polypeptides that are I53dn5B or variants thereof, where the plurality of first components and the plurality of second components non-covalently interact to form a nanostructure; and wherein the nanostructure exhibits a plurality of copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof.

The invention discloses an LAMP (loop-medicated isothermal amplification) detection kit for metapneumovirus. The kit internally comprises a primer set formed by six primers designed aiming at eight regions of a metapneumovirus F gene conserved region, wherein the nucleotide sequence of the primer set is as shown in a sequence table from sequence 1 to sequence 6. The detection kit disclosed by the invention can be used for specifically detecting the metapneumovirus, wherein the minimum detection limit of the detection kit is 100fg / muL, and the sensitivity of the detection kit is 100 times as high as that of the normal RT-PCR (reverse transcription-polymerase chain reaction). The LAMP detection kit is quick to detect, low in cost, free from expensive apparatuses, simpler in operation method, and suitable for the quick detection in the clinic.

The invention discloses multifunctional sterilization and disinfection incense as well as a preparation method and application thereof. The multifunctional sterilization and disinfection incense is mainly prepared from folium artemisiae argyi stems, rhizoma atractylodis rhizomes, agastache rugosus leaf stems, wild chrysanthemum flowers, asarum, rhizoma nardostachyos, acorus calamus and spices. The traditional Chinese medicine composition has sterilization and disinfection effects, mosquito and fly killing effects and effects of pre-controlling and inhibiting viruses and germs such as new coronal pneumovirus and diplococcus pneumoniae in a human body, the pre-controlling rate reaches 35% or above through smoking contrast practice tests, and the immune effect rate is increased by 25% or above.

The present invention relates to the use of a pneumovirus NS1 protein and / or NS2 protein or a nucleic acid encoding pneumovirus NS1 protein and / or NS2 protein for the preparation of a pharmaceutical formulation for reducing the immune response mediated by interferon (IFN). The invention further relates to recombinant pneumoviruses, in particular respiratory syncytial viruses (RSV), having an increased, reduced, or lacking a resistance to the interferon (IFN) mediated immune response, recombinant viruses having an increased resistance to the interferon (IFN) mediated immune response, and the use of the viruses in pharmaceutical applications, e.g. as vaccines.

The application provides preparations, methods and substituted thieno[3,2-d]pyrimidines, furo[3,2-d]pyrimidines and pyrrolo[ 3,2‑d]pyrimidine compounds, wherein the pneumovirinae virus infection includes respiratory syncytial virus infection, and thieno[3,2‑d]pyrimidine, furo[3,2 Processes and intermediates for ‑d]pyrimidine and pyrrolo[3,2‑d]pyrimidine compounds.